Back to Search
Start Over
Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.
- Source :
-
Autoimmunity Reviews . Jul2020, Vol. 19 Issue 7, pN.PAG-N.PAG. 1p. - Publication Year :
- 2020
-
Abstract
- Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear. This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy. An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively). These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]
- Subjects :
- *SARS-CoV-2
*COVID-19
*HYDROXYCHLOROQUINE
*RHEUMATOLOGISTS
*INFECTION
Subjects
Details
- Language :
- English
- ISSN :
- 15689972
- Volume :
- 19
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Autoimmunity Reviews
- Publication Type :
- Academic Journal
- Accession number :
- 143557906
- Full Text :
- https://doi.org/10.1016/j.autrev.2020.102566